Vaneltix Pharma, Inc. is a clinical phase biotech focused on Urology and Women’s Health Care, working on de-risked assets in areas of high unmet clinical need. Vaneltix is seeking to partner with new investors to help prepare the company for a potential exit in 18-24 months.